OCT4 is superior to CD30 in the diagnosis of metastatic embryonal carcinomas after chemotherapy

Ming Tse Sung, Timothy D. Jones, Stephen D. Beck, Richard S. Foster, Liang Cheng

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Correctly diagnosing a metastatic germ cell tumor after chemotherapy may be challenging because of the diverse morphological manifestations of postchemotherapy tumors. Both OCT4 and CD30 are sensitive markers for the identification of primary embryonal carcinomas; however, loss of expression of CD30 (65%) has been reported in metastatic embryonal carcinomas after chemotherapy. The present study was conducted to evaluate the expression patterns of OCT4 and CD30 in postchemotherapy metastatic embryonal carcinomas and to compare their utility as diagnostic tools. Twenty-five cases of metastatic embryonal carcinoma after chemotherapy were immunohistochemically analyzed for CD30, OCT4, and cytokeratin AE1/AE3 expression. The staining intensities and the percentages of positively staining tumor cells were recorded. Nineteen (76%) of 25 cases revealed diffuse, moderate to strong nuclear OCT4 staining in postchemotherapy embryonal carcinomas. Among these 19 OCT4-positive cases, 8 also revealed diffuse and moderate to strong membranous CD30 staining. Seven of these OCT4-positive cases retained focal and weak CD30 expression. The remaining 4 OCT4-positive cases demonstrated a complete loss of CD30 expression. The 19 OCT4-positive cases showed a positive but variable cytokeratin AE1/AE3 expression pattern. Six (24%) of 25 cases were negative for both CD30 and OCT4 but demonstrated diffuse and strong cytokeratin AE1/AE3 staining. OCT4 is a useful diagnostic marker to identify metastatic embryonal carcinomas after chemotherapy, with a better sensitivity than CD30.

Original languageEnglish (US)
Pages (from-to)662-667
Number of pages6
JournalHuman pathology
Volume37
Issue number6
DOIs
StatePublished - Jun 1 2006

Fingerprint

Embryonal Carcinoma
Drug Therapy
Staining and Labeling
Keratins
Germ Cell and Embryonal Neoplasms
Neoplasms

Keywords

  • Biomarker
  • CD30
  • Chemotherapy
  • Cytokeratin AE1/AE3
  • Embryonal carcinoma
  • Germ cell tumor
  • Metastasis
  • Neoplasia
  • OCT3/4
  • Testis

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

OCT4 is superior to CD30 in the diagnosis of metastatic embryonal carcinomas after chemotherapy. / Sung, Ming Tse; Jones, Timothy D.; Beck, Stephen D.; Foster, Richard S.; Cheng, Liang.

In: Human pathology, Vol. 37, No. 6, 01.06.2006, p. 662-667.

Research output: Contribution to journalArticle

Sung, Ming Tse ; Jones, Timothy D. ; Beck, Stephen D. ; Foster, Richard S. ; Cheng, Liang. / OCT4 is superior to CD30 in the diagnosis of metastatic embryonal carcinomas after chemotherapy. In: Human pathology. 2006 ; Vol. 37, No. 6. pp. 662-667.
@article{517ac49059624f05bd94cd4e32edd6da,
title = "OCT4 is superior to CD30 in the diagnosis of metastatic embryonal carcinomas after chemotherapy",
abstract = "Correctly diagnosing a metastatic germ cell tumor after chemotherapy may be challenging because of the diverse morphological manifestations of postchemotherapy tumors. Both OCT4 and CD30 are sensitive markers for the identification of primary embryonal carcinomas; however, loss of expression of CD30 (65{\%}) has been reported in metastatic embryonal carcinomas after chemotherapy. The present study was conducted to evaluate the expression patterns of OCT4 and CD30 in postchemotherapy metastatic embryonal carcinomas and to compare their utility as diagnostic tools. Twenty-five cases of metastatic embryonal carcinoma after chemotherapy were immunohistochemically analyzed for CD30, OCT4, and cytokeratin AE1/AE3 expression. The staining intensities and the percentages of positively staining tumor cells were recorded. Nineteen (76{\%}) of 25 cases revealed diffuse, moderate to strong nuclear OCT4 staining in postchemotherapy embryonal carcinomas. Among these 19 OCT4-positive cases, 8 also revealed diffuse and moderate to strong membranous CD30 staining. Seven of these OCT4-positive cases retained focal and weak CD30 expression. The remaining 4 OCT4-positive cases demonstrated a complete loss of CD30 expression. The 19 OCT4-positive cases showed a positive but variable cytokeratin AE1/AE3 expression pattern. Six (24{\%}) of 25 cases were negative for both CD30 and OCT4 but demonstrated diffuse and strong cytokeratin AE1/AE3 staining. OCT4 is a useful diagnostic marker to identify metastatic embryonal carcinomas after chemotherapy, with a better sensitivity than CD30.",
keywords = "Biomarker, CD30, Chemotherapy, Cytokeratin AE1/AE3, Embryonal carcinoma, Germ cell tumor, Metastasis, Neoplasia, OCT3/4, Testis",
author = "Sung, {Ming Tse} and Jones, {Timothy D.} and Beck, {Stephen D.} and Foster, {Richard S.} and Liang Cheng",
year = "2006",
month = "6",
day = "1",
doi = "10.1016/j.humpath.2006.01.019",
language = "English (US)",
volume = "37",
pages = "662--667",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - OCT4 is superior to CD30 in the diagnosis of metastatic embryonal carcinomas after chemotherapy

AU - Sung, Ming Tse

AU - Jones, Timothy D.

AU - Beck, Stephen D.

AU - Foster, Richard S.

AU - Cheng, Liang

PY - 2006/6/1

Y1 - 2006/6/1

N2 - Correctly diagnosing a metastatic germ cell tumor after chemotherapy may be challenging because of the diverse morphological manifestations of postchemotherapy tumors. Both OCT4 and CD30 are sensitive markers for the identification of primary embryonal carcinomas; however, loss of expression of CD30 (65%) has been reported in metastatic embryonal carcinomas after chemotherapy. The present study was conducted to evaluate the expression patterns of OCT4 and CD30 in postchemotherapy metastatic embryonal carcinomas and to compare their utility as diagnostic tools. Twenty-five cases of metastatic embryonal carcinoma after chemotherapy were immunohistochemically analyzed for CD30, OCT4, and cytokeratin AE1/AE3 expression. The staining intensities and the percentages of positively staining tumor cells were recorded. Nineteen (76%) of 25 cases revealed diffuse, moderate to strong nuclear OCT4 staining in postchemotherapy embryonal carcinomas. Among these 19 OCT4-positive cases, 8 also revealed diffuse and moderate to strong membranous CD30 staining. Seven of these OCT4-positive cases retained focal and weak CD30 expression. The remaining 4 OCT4-positive cases demonstrated a complete loss of CD30 expression. The 19 OCT4-positive cases showed a positive but variable cytokeratin AE1/AE3 expression pattern. Six (24%) of 25 cases were negative for both CD30 and OCT4 but demonstrated diffuse and strong cytokeratin AE1/AE3 staining. OCT4 is a useful diagnostic marker to identify metastatic embryonal carcinomas after chemotherapy, with a better sensitivity than CD30.

AB - Correctly diagnosing a metastatic germ cell tumor after chemotherapy may be challenging because of the diverse morphological manifestations of postchemotherapy tumors. Both OCT4 and CD30 are sensitive markers for the identification of primary embryonal carcinomas; however, loss of expression of CD30 (65%) has been reported in metastatic embryonal carcinomas after chemotherapy. The present study was conducted to evaluate the expression patterns of OCT4 and CD30 in postchemotherapy metastatic embryonal carcinomas and to compare their utility as diagnostic tools. Twenty-five cases of metastatic embryonal carcinoma after chemotherapy were immunohistochemically analyzed for CD30, OCT4, and cytokeratin AE1/AE3 expression. The staining intensities and the percentages of positively staining tumor cells were recorded. Nineteen (76%) of 25 cases revealed diffuse, moderate to strong nuclear OCT4 staining in postchemotherapy embryonal carcinomas. Among these 19 OCT4-positive cases, 8 also revealed diffuse and moderate to strong membranous CD30 staining. Seven of these OCT4-positive cases retained focal and weak CD30 expression. The remaining 4 OCT4-positive cases demonstrated a complete loss of CD30 expression. The 19 OCT4-positive cases showed a positive but variable cytokeratin AE1/AE3 expression pattern. Six (24%) of 25 cases were negative for both CD30 and OCT4 but demonstrated diffuse and strong cytokeratin AE1/AE3 staining. OCT4 is a useful diagnostic marker to identify metastatic embryonal carcinomas after chemotherapy, with a better sensitivity than CD30.

KW - Biomarker

KW - CD30

KW - Chemotherapy

KW - Cytokeratin AE1/AE3

KW - Embryonal carcinoma

KW - Germ cell tumor

KW - Metastasis

KW - Neoplasia

KW - OCT3/4

KW - Testis

UR - http://www.scopus.com/inward/record.url?scp=33745448237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745448237&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2006.01.019

DO - 10.1016/j.humpath.2006.01.019

M3 - Article

C2 - 16733205

AN - SCOPUS:33745448237

VL - 37

SP - 662

EP - 667

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 6

ER -